Case report

Successful stenting of the ductus venosus in 2 neonates with asplenia syndrome complicated by infracardiac type total anomalous pulmonary venous connection

Takashi Higaki (MD)a,b,* Eiichi Yamamoto (MD)a,b, Takeshi Nakano (MD)a, Masaaki Ohta (MD)a, Hidemi Takata (MD)a, Kikuko Murao (MD)a, Toshiyuki Chisaka (MD)a, Tomozo Moritani (MD)a, Mitsugi Nagashima (MD)c, Fumiaki Shikata (MD)c, Eiichi Ishii (MD)a

a Department of Pediatrics, Ehime University Graduate School of Medicine, Ehime, Japan
b Department of Pediatric Cardiology, Stroke & Cardiovascular Center, Ehime University Hospital, Ehime, Japan
c Department of Cardiovascular Surgery, Stroke & Cardiovascular Center, Ehime University Hospital, Ehime, Japan

Received 12 October 2009; received in revised form 26 October 2009; accepted 28 October 2009

KEYWORDS
Ductus venosus; Stent implantation; Asplenia syndrome; Total anomalous pulmonary venous connection; Catheter intervention

Summary In the neonatal period, the surgical mortality of palliation is extremely high for asplenia syndrome complicated by single ventricle combined with total anomalous pulmonary venous connection (TAPVC). Recently, stent implantation for the pulmonary venous drainage route soon after birth has been used instead of surgery to prevent pulmonary venous occlusion and to maintain stable hemodynamics in the neonatal period or in early infancy. Here, we successfully implanted stents in the ductus venosus (DV) in 2 neonates with asplenia syndrome complicated by infracardiac type TAPVC. The first patient was a 3-day-old male neonate with severe cyanosis. Immediately after TAPVC was diagnosed, we implanted a stent in the DV. The second patient was a 0-day-old female neonate. She was diagnosed as TAPVC by fetal echocardiogram. After the scheduled delivery, a stent was successfully implanted. We believe that stent implantation in the DV in the neonatal period is effective and less invasive than surgery in patients with infracardiac type TAPVC.

© 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.

Introduction

The fate of infants with functional single ventricle such as in asplenia syndrome complicated by total anomalous pulmonary venous connection (TAPVC) is catastrophic compared to that of infants without TAPVC [1]. The current
surgical mortality of isolated TAPVC is less than 10% and most patients successfully survive, while the outcome is unfavorable for patients with associated complex cardiac malformations [2]. It has been reported that an early age at initial operation, the need of palliative surgery with cardiopulmonary bypass, and an obstructed TAPVC are risk factors for mortality in these patients [1,2]. Even though the surgical outcome has recently been improving in these patients [1,3,4], mortality is still high among patients with heterotaxy treated in the modern surgical era [5], and this situation continues to remain extremely challenging [6]. Patients with obstructed TAPVC, especially of the infracardiac type, usually present with critical illness. This requires alternative and aggressive management strategies, for instance, a stent implantation to maintain the pulmonary venous drainage and stable hemodynamics in the neonatal period or early infancy [2,7].

We successfully implanted stents in the ductus venosus (DV) in 2 neonates with asplenia syndrome complicated by infracardiac type TAPVC [8]. Our novel strategy, stent implantation in the DV, may be a better alternative to early surgery for the treatment of infracardiac type TAPVC in asplenia syndrome.

Case reports

Patient 1

A 3-day-old male neonate, who was born at 39 weeks of gestation with a birth weight of 3000 g, was referred to our hospital with complaints of severe cyanosis. At admission, the SpO2 was 55%. Physical examination and echocardiogram revealed that the patient had asplenia syndrome, situs ambiguous, D-loop, D-transposition (A, D, D), single right ventricle, common atrium, pulmonary atresia, common atrioventricular canal defect, patent ductus arteriosus, infracardiac type TAPVC, right aortic arch, and bilateral superior vena cava. His cyanosis gradually improved by the administration of lipo-prostaglandin E1; however, the pulmonary congestion progressed with closing DV (Fig. 1). At 3 days of admission, cardiac catheterization and stent implantation in the DV was performed as follows. First, the umbilical vein was secured using a 6F sheath. A 6F multipurpose catheter was inserted into the portal vein through the umbilical vein. Portal venogram was used to find the exact route of the DV. Through the DV, a guide wire (0.014 in.) was carefully inserted into the common atrium. Since the DV had already started to close, it was difficult to pass the guide wire through the DV. Keeping the guide wire in the common atrium, a stent mounted on the balloon catheter was introduced over the guide wire and the stent was located in the DV. We successfully implanted the stents (GFX Micro-stents, 1 piece of diameter 3 mm and length 24 mm, and 2 pieces of diameter 3 mm and length 18 mm) in the DV from the atrium to the portal vein (Fig. 2). We confirmed that the flow through the DV was adequate by both angiogram and echocardiogram. Biphasic flow pattern was detected in the stent by a Doppler echocardiogram. Chest X-ray revealed that pulmonary congestion had disappeared. After the procedure, heparin (100 U/(kg day), intravenously) and aspirin (5 mg/(kg day), orally) were administered. Pul-
Stenting of the ductus venosus

At the age of 3 months, to maintain an optimal flow for a long period. A sufficient case demonstrated the importance of using a larger stent. A stent with a larger diameter was selected since the first stent (Palmaz stent 2408 of diameter 8 mm and length 24 mm) in the DV.

In the first patient, the restenosis of the DV caused by intimal proliferation occurred 1 month after the procedure, and redilation of the stent up to 5 mm in size was eventually required. In our experience, the appropriate size of the stent was at least 8 mm for these neonates; the best size of the stent for longer patency should be investigated in the future.

In conclusion, stent implantation in the DV soon after birth is an effective and less invasive therapy for neonates with complex congenital heart disease, particularly with infracardiac type TAPVC.

Discussion

This is the first report of successful stent implantation in the DV in 2 newborns with asplenia syndrome with infracardiac type TAPVC in order to prevent pulmonary venous occlusion and maintain an adequate flow from the pulmonary vein into the atrium.

In asplenia syndrome complicated by infracardiac type TAPVC, pulmonary congestion progresses rapidly after the closure of the DV. The mortality rate of the palliative surgery is extremely high for TAPVC in the neonatal period. As a result, the prognosis of asplenia syndrome with infracardiac type TAPVC remains poor [1,3,4]. Therefore, an alternative method is required in order to treat TAPVC in the neonatal period. Catheter intervention is one of the most important treatments in complex heart diseases [7,9]. Our novel strategy, stent implantation in the DV, is effective and less invasive than early surgery.

Since the DV closes quickly after birth, stent implantation in the DV becomes very difficult as the infant grows older. Consequently, this condition has to be diagnosed immediately and our procedure should be performed as soon as possible before the closure of the DV. For better results, intrapericardial diagnosis by fetal echocardiogram should be performed, followed by pre-mediated delivery and subsequent stent implantation.

In the first patient, the restenosis of the DV caused by intimal proliferation occurred 1 month after the procedure, and redilation of the stent up to 5 mm in size was eventually required. In our experience, the appropriate size of the stent was at least 8 mm for these neonates; the best size of the stent for longer patency should be investigated in the future.

Most importantly, stent implantation in the DV soon after birth could delay the requirement for surgery with cardiopulmonary bypass in the neonatal period. Myocardial ischemia following cardiopulmonary bypass may cause deleterious cardiac dysfunction in neonates after surgery. These adverse effects may lead to high mortality after cardiac surgery in these patients. Our strategy is less invasive and is intended to improve the prognosis of patients with asplenia syndrome with infracardiac type TAPVC.

In conclusion, stent implantation in the DV soon after birth is an effective and less invasive therapy for neonates with complex congenital heart disease, particularly with infracardiac type TAPVC.

References


A female neonate was born at 38 weeks of gestation with a birth weight of 2580 g by scheduled Cesarean section. The patient was diagnosed with asplenia syndrome (A, D, D), single right ventricle, common atrium, pulmonary atresia, common atrioventricular canal, patent ductus arteriosus, infracardiac type TAPVC, and bilateral superior vena cava according to the fetal echocardiogram. We successfully performed a stent implantation in the DV after birth. As described for Patient 1, we implanted the stents (Palmaz stent 2408 of diameter 8 mm and length 24 mm) in the DV. A stent with a larger diameter was selected since the first case demonstrated the importance of using a larger stent to maintain an optimal flow for a long period. A sufficient flow through the DV was maintained and redilation of the stent was not required (Fig. 3). At the age of 3 months, TAPVC repair, right ventricle-pulmonary artery shunt, and pulmonary artery angioplasty were performed.

Patient 2

A female neonate was born at 38 weeks of gestation with a birth weight of 2580 g by scheduled Cesarean section. The patient was diagnosed with asplenia syndrome (A, D, D), single right ventricle, common atrium, pulmonary atresia, common atrioventricular canal, patent ductus arteriosus, infracardiac type TAPVC, and bilateral superior vena cava according to the fetal echocardiogram. We successfully performed a stent implantation in the DV after birth. As described for Patient 1, we implanted the stents (Palmaz stent 2408 of diameter 8 mm and length 24 mm) in the DV. A stent with a larger diameter was selected since the first case demonstrated the importance of using a larger stent to maintain an optimal flow for a long period. A sufficient flow through the DV was maintained and redilation of the stent was not required (Fig. 3). At the age of 3 months, TAPVC repair, right ventricle-pulmonary artery shunt, and pulmonary artery angioplasty were performed.

Discussion

This is the first report of successful stent implantation in the DV in 2 newborns with asplenia syndrome with infracardiac type TAPVC in order to prevent pulmonary venous occlusion and maintain an adequate flow from the pulmonary vein into the atrium.

In asplenia syndrome complicated by infracardiac type TAPVC, pulmonary congestion progresses rapidly after the closure of the DV. The mortality rate of the palliative surgery is extremely high for TAPVC in the neonatal period. As a result, the prognosis of asplenia syndrome with infracardiac type TAPVC remains poor [1,3,4]. Therefore, an alternative method is required in order to treat TAPVC in the neonatal period. Catheter intervention is one of the most important treatments in complex heart diseases [7,9]. Our novel strategy, stent implantation in the DV, is effective and less invasive than early surgery.

Since the DV closes quickly after birth, stent implantation in the DV becomes very difficult as the infant grows older. Consequently, this condition has to be diagnosed immediately and our procedure should be performed as soon as possible before the closure of the DV. For better results, intrapericardial diagnosis by fetal echocardiogram should be performed, followed by pre-mediated delivery and subsequent stent implantation.

In the first patient, the restenosis of the DV caused by intimal proliferation occurred 1 month after the procedure, and redilation of the stent up to 5 mm in size was eventually required. In our experience, the appropriate size of the stent was at least 8 mm for these neonates; the best size of the stent for longer patency should be investigated in the future.

Most importantly, stent implantation in the DV soon after birth could delay the requirement for surgery with cardiopulmonary bypass in the neonatal period. Myocardial ischemia following cardiopulmonary bypass may cause deleterious cardiac dysfunction in neonates after surgery. These adverse effects may lead to high mortality after cardiac surgery in these patients. Our strategy is less invasive and is intended to improve the prognosis of patients with asplenia syndrome with infracardiac type TAPVC.

In conclusion, stent implantation in the DV soon after birth is an effective and less invasive therapy for neonates with complex congenital heart disease, particularly with infracardiac type TAPVC.

References


